01/08/2014 03:48:56 Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
07/29/20144:48PMDJNPfizer Still Looking to Buy; Results Beat Views -- 2nd Update
By Jonathan D. Rockoff and Michael Calia Pfizer Inc. said Tuesday it was looking at potential deals, including big ones, after earlier dropping its pursuit of British rival AstraZeneca PLC. The New York pharmaceutical company said U.K. takeover rules didn't allow it to consider reviving its interest in AstraZeneca for... More...>>
07/29/20144:33PMDJNMARKET SNAPSHOT: U.S. Stocks End Choppy Trade Lower
By Anora Mahmudova and Carla Mozee, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks ended Tuesday's choppy trading session lower, as investors turned cautious after the European Union and the President Barack Obama announced a new round of sanctions against Russia for its role in Ukraine's deadly civil war. The European... More...>>
07/29/20144:26PMDJNMARKET SNAPSHOT: U.S. Stocks End Choppy Trade Lower
By Anora Mahmudova and Carla Mozee, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks ended Tuesday's choppy trading session lower, as investors turned cautious after the EU announced a new round of sanctions against Russia for its role in Ukraine's deadly civil war. The European Union and the U.S. on Tuesday extended... More...>>
07/29/20144:24PMDJNMARKET SNAPSHOT: U.S. Stocks End Choppy Trade Lower
By Anora Mahmudova and Carla Mozee, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks ended Tuesday's choppy trading session lower, as investors turned cautious after the EU announced a new round of sanctions against Russia for its role in Ukraine's deadly civil war. The European Union and the U.S. on Tuesday extended... More...>>
07/29/201410:39AMDJNMARKET SNAPSHOT: U.S. Stocks Rise; Dow Above 17,000
By Anora Mahmudova and Carla Mozee, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks rose on Tuesday, with gains pushing the Dow Jones Industrial Average above 17,000, while the S&P 500 hovered near record levels as estimate-beating corporate earnings and better-than-expected consumer confidence data lifted sentiment... More...>>
07/29/20149:50AMDJNMARKET SNAPSHOT: U.S. Stocks Open Higher; Dow Above 17,000
By Anora Mahmudova and Carla Mozee, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks opened higher Tuesday with modest gains pushing the Dow Jones Industrial Average above 17,000, thanks to prices gains in Merck & Co and Pfizer Inc following better-than-expected quarterly results. The S&P 500 (SPX) opened up 3... More...>>
07/29/20149:48AMDJNMARKET SNAPSHOT: U.S. Stocks Open Higher; Dow Above 17,000
By Anora Mahmudova and Carla Mozee, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks opened higher Tuesday with modest gains pushing the Dow Jones Industrial Average above 17,000, thanks to prices gains in Merck & Co and Pfizer Inc following better-than-expected quarterly results. The S&P 500 (SPX) opened up 3... More...>>
07/29/20149:33AMDJNMARKET SNAPSHOT: U.S. Stocks: Futures Rise; Housing Prices Next
By Anora Mahmudova and Carla Mozee, MarketWatch NEW YORK (MarketWatch) -- U.S. stock futures rose Tuesday, following better-than-expected quarterly results from drug makers including Merck & Co. Reaction to a fall in home prices on a seasonally adjusted bases was muted. Investors are next set to assess confidence among... More...>>
07/29/20149:06AMDJNMARKET SNAPSHOT: U.S. Stocks: Futures Rise; Housing Prices Next
By Anora Mahmudova and Carla Mozee, MarketWatch NEW YORK (MarketWatch) -- U.S. stock futures rose Tuesday, following better-than-expected quarterly results from drug makers including Merck & Co. Investors are next set to assess reports that may show some slowing in U.S. housing prices and confidence among U.S. consumers... More...>>
07/29/20148:15AMDJNMARKET SNAPSHOT: U.S. Stocks: Futures Rise After Merck, Pfizer Results
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- U.S. stock futures rose Tuesday, following better-than-expected quarterly results from drug makers including Merck & Co. Investors are next set to assess reports that may show some slowing in U.S. housing prices and confidence among U.S. consumers. Futures for the... More...>>
07/29/20148:08AMDJNMARKET SNAPSHOT: U.S. Stocks: Futures Rise After Merck, Pfizer Results
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- U.S. stock futures rose Tuesday, following better-than-expected quarterly results from drug makers including Merck & Co. Investors are next set to assess reports that may show some slowing in U.S. housing prices and confidence among U.S. consumers. Futures for the... More...>>
07/29/20147:09AMDJNMARKET SNAPSHOT: U.S. Stocks: Futures Choppy Before Confidence Report
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- U.S. stock futures indicated a choppy open for Wall Street Tuesday, ahead of reports expected to show some slowing in U.S. housing prices and confidence among U.S. consumers. The market will also assess a round of quarterly results from the health sector, including Aetna... More...>>
07/29/20146:56AMBWMerck Announces Second-Quarter 2014 Financial Results
Second-Quarter 2014 Non-GAAP EPS of $0.85, Excluding Certain Items, and GAAP EPS of $0.68 2014 Full-Year Non-GAAP EPS Target of $3.43 to $3.53, Excluding Potential Venezuelan Bolivar Devaluation and Certain Other Items; 2014 Full-Year GAAP EPS Target of $4.44 to $4.77 2014 Full-Year Non-GAAP EPS Target Includes $0.06 to... More...>>
07/29/20146:07AMDJNMARKET SNAPSHOT: U.S. Stocks: Futures Decline Before Confidence Report
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- U.S. stock futures indicated a slightly lower open for Wall Street Tuesday, ahead of reports expected to show some slowing in U.S. housing prices and confidence among U.S. consumers. The market will also assess a round of quarterly results from the health sector, including... More...>>
07/24/20148:30AMBWMerck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection i...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent. The multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of letermovir... More...>>
07/23/201412:15PMBWMerck Announces Fourth-Quarter 2014 Dividend
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.44 per share of the company’s common stock for the fourth quarter of 2014. Payment will be made on October 7, 2014, to stockholders of record at the close of business... More...>>
07/17/20148:30AMPRNUSMerck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Women's Netwo...
Merck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Women's Network - USA to Encourage Women Living with HIV to be "Vocal" about their Treatment "Speaking Up" is Vital, Given the Significant Impact of the Disease on Women PR Newswire WHITEHOUSE... More...>>
07/07/20143:20PMDJNNovartis Wins 'Breakthrough' Status for Leukemia Treatment
ZURICH-- Novartis AG said Monday the U.S. Food and Drug Administration designated a new leukemia treatment it is developing as a "breakthrough" therapy, giving it access to a potentially faster regulatory review process. Basel-based Novartis's CTL019 treatment, which is being tested at the University of Pennsylvania's... More...>>
06/30/20148:00AMBWMerck Announces Data from Investigational Phase 3 Study on EMEND® (aprepitant) for the Prevention of Chemotherapy-Induced Na...
Merck Planning Regulatory Submissions in the U.S. for EMEND® in Pediatric Setting Including New Suspension Formulation in Second Half of 2014 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of... More...>>
06/30/20146:00AMBWMerck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced ...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company’s investigational anti-PD-1 antibody, for the treatment of advanced melanoma. If approved... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk140801 03:48